Chardan Capital Upgrades Pharma Mar (OTCMKTS:PHMMF) to Strong-Buy

Pharma Mar (OTCMKTS:PHMMF) was upgraded by Chardan Capital to a “strong-buy” rating in a report issued on Thursday, Zacks.com reports.

Pharma Mar Stock Performance

Shares of PHMMF stock opened at $34.26 on Thursday. Pharma Mar has a 52-week low of $26.85 and a 52-week high of $46.26. The company has a current ratio of 2.63, a quick ratio of 2.22 and a debt-to-equity ratio of 0.14. The stock has a fifty day simple moving average of $32.89 and a two-hundred day simple moving average of $33.95.

About Pharma Mar

Pharma Mar, SA, a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments.